The content on this site is intended for healthcare professionals only
Dr Sundar Jagannath speaks to ecancer about the results from the LINKER-MM1 clinical trial, testing the safety and efficacy of linvoseltamab (a B-cell maturation antigen × CD3 antibody) as a treatment for relapsed/refractory multiple myeloma (RRMM).
The primary endpoint of this study was objective response rate per Independent Review Committee (IRC).
Secondary endpoints included duration of response, progression free survival, overall survival, and safety.
The study found that linvoseltamab induced high rates of deep and durable responses in patients with RRMM including those in high-risk subgroups.
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
